Dr Montiel-Duarte is a Senior Lecturer in Biochemistry and her main contributions to teaching at NTU are in the field of Biochemistry and Cell Biology. Dr Montiel-Duarte is Module leader for Metabolism and its Control (Level Two), Research Project (Level Three), Short Dissertation (Level Three), and she is involved as a lecturer in other undergraduate modules (e.g. Clinical Biochemistry, Level Two). Dr Montiel-Duarte is also a PhD supervisor and her research interests include gene regulation and cell signalling.
Dr Montiel-Duarte is a Licentiate (BSc + MSc) in Biochemistry, a Licentiate (BSc + MSc) in Biology, and has a PhD in Biochemistry.
She has been a lecturer at NTU since 2010 and her previous roles were:
- Postdoctoral Fellow, School of Pharmacy, University of Nottingham (2005-2008)
- Research Associate, Biochemistry Department, University of Leicester (2004-2005)
- Postdoctoral Fellow, Molecular Biology Department, Cell Therapy Area, University Hospital of Navarra (2002-2004)
Dr Montiel-Duarte has been involved in the following projects:
- Identification of a conserved motif that mediates interaction of the oncogenic corepressor protein BCL11A with retinoid receptors and COUP-TF
- Alterations in cell cycle and apoptosis pathways mediated by BCR-ABL1 oncogene in chronic myelogenous leukemia and acute lymphoblastic leukemia with Philadelphia chromosome
- Characterization of the apoptotic process induced by 3,4-methilendioxymethamphetamine (MDMA) in hepatocytes and stellate cells
- Signalling pathways related to MDMA, TNF-alpha, IGF-I and TGF-beta in collagen production by hepatic stellate cells
- Collagen production in hypertensive rats
Dr Montiel-Duarte's interest is currently focused in de-regulated signalling pathways in chronic myeloid leukaemia and in gene regulation.
Opportunities to carry out postgraduate research towards an MPhil or PhD exist, and further information may be obtained from the NTU Graduate School.
Sponsors and collaborators
Recent research is conducted with the collaboration, funding and / or support of:
- Santander Mobility Award (£1,000)
- Dr Maria Iraburu (University of Navarra, Spain)
Dr Montiel-Duarte’s research support in the past includes:
- Summer Studentship from the Wellcome Trust, 2013 (£1,080)
- Santander Research Mobility Award, in collaboration with Dr Colombo and Dr Dickins (£5,000)
- Summer Studentship from the Wellcome Trust, 2007 (£1,440)
- Summer Studentship from the Biochemical Society, 2007 (£1,280)
- Ramon Areces Foundation supported Dr Montiel-Duarte's early research work in the UK, 2004-2006 (€48,000)
- A signature motif mediating selective interactions of BCL11A with the NR2E/F subfamily of orphan nuclear receptors. Chan CM, Fulton J, Montiel-Duarte C, Collins HM, Bharti N, Wadelin FR, Moran PM, Mongan NP, Heery DM, Nucleic Acids Research, 2013, 41 (21)
- Interleukin-4-inducing principle from Schistosoma mansoni eggs contains a functional C-terminal nuclear localization signal necessary for nuclear translocation in mammalian cells but not for its uptake. Kaur I, Schramm G, Everts B, Scholzen T, Kindle KB, Beetz C, Montiel-Duarte C, Blindow S, Jones AT, Haas H, Stolnik S, Heery DM and Falcone FH, Infection and Immunity, 2011, 79 (4), 1779-1788
- Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Montiel-Duarte C, Cordeu L, Agirre X, Roman-Gomez J, Jimenez- Velasco A, San Jose-eneriz E, Garate L, Andreu EJ, Calasanz MJ, Heiniger A, Torres A and Prosper F, Leukaemia Research, 2008, 32 (5), 709-716
- Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK path. Lopez-Pederea C, Bunendia P, Cuadrado MJ, Siendonies E, Aguirre MA, Barbarroja N., Montiel-Duarte C, Torres A, Khamashta M and Velasco F, Arthritis & Rheumatism, 2006, 54 (1), 301-311
- ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Agirre X, Roman-Gomez J, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vazquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD and Prosper F, Oncogene, 2006, 25 (13) , 1862-1870
- Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD and Prosper F, 2006, International Journal of Cancer, 118 (8), 1945-1953
- BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27 Kip1 degradation and proliferation of chronic myelogenous leukemia cells, Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, Montiel-Duarte C, Rifon J, Perez-Calvo J, Arbona C, Prosper F and Perez-Roger I, Cancer Research, 2005, 65 (8), 3264-3272
- Role of reactive oxygen species, glutathione and NF-kB in apoptosis induced by 3,4-methylenedioxymethamphetamine (''Ecstasy'') on hepatic stellate cells. Montiel-Duarte C, Varela-Rey M, Oses-Prieto JA, Lopez-Zabalza, MJ Beitia G, Cenarruzabita E and Iraburu MJ, Biochemical Pharmacology, 2004, 67, 1025-1033